Michel de Rosen

hideThis article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) This biography of a living person needs additional citations for verification. Please help by adding reliable sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately, especially if potentially libelous or harmful. Find sources:  –  ·  ·  · scholar · JSTOR (June 2012) (Learn how and when to remove this template message) This article's use of external links may not follow Wikipedia's policies or guidelines. Please by removing excessive or inappropriate external links, and converting useful links where appropriate into footnote references. (December 2012) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Michel de Rosen of Eutelsat

Michel de Rosen (born February 18, 1951) is the chairman of Faurecia^[1] and was the CEO of Eutelsat Communications^[2] from 2009 to 2016. He is a non-executive member of the board of directors of ABB. He was chief executive officer and chairman of the board of directors of ViroPharma from August 2002 to May 2008. From 1982 to 1999, de Rosen held several positions at Rhône-Poulenc (France) and Rhone-Poulenc Rorer (USA) (now Sanofi-Aventis), including chief executive officer from May 1995 until December 1999, and chairman of the board of directors from 1996 to 1999.

Career[]

From 1976 to 1982 de Rosen was auditor at the French Ministries of Finance and Defense.

Education[]

Michel de Rosen holds an Master of Business Administration from HEC Paris.

Organizations[]

Michel de Rosen is or has been on a number of boards:

• ABB (director, since 2002);
• Aspen Institute [1] (mentor)
• Global Business Coalition on HIV/AIDS [2] (director)
• HTH Worldwide [3];(advisor)
• InnaPhase Corporation (director, July 2000 - September 2004)
• Pennsylvania Bio [4] (director)
• Ursinus College [5] (trustee)

In an interview with the British newspaper The Sunday Telegraph on October 8, 1995, he was quoted as saying that he ... sees RPR as a mixture of 'hunting' – growing the company by swooping on acquisition 'prey' – and 'farming', less glamorous but vital organic growth and development of new drugs.

References[]